Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (November 2016)
21 slides from Inspiremd's investor presentation, Nov 15, 2016
Slide 1: Corporate Presentation
inspireMD Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspirelMD This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For
Slide 3: About InspireMD
About InspireMD inspireMD Commercial-stage medical device company marketing and developing innovative embolic prevention systems (EPS), neurovascular devices and thrombus management technologies ' > ee Es | a OLOGY PRODUCTS iit; Proprieta oNe Commerci eoce pe CGuard™ Carotid EPS prod eeking a narion
Slide 4: Investment Highlights
Investment Highlights inspireMD + Revenue growth driven by broader EU sales and Latin American launch of CGuard™ * Strategic distribution partnership with Penumbra (NYSE: PEN) + Multiple and consistent clinical trial results using CGuard in a broad patient population, including high risk patients *
Slide 5: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD “Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization,
Slide 6: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit ~—Se to Stroke Inspir eMD Pre-Procedure Post-Procedure Pre-intervention showing 90% occlusion of the Post-intervention showing successful opening carotid artery and an MRI showing an old white of the occluded carotid artery with conventional matter infarc
Slide 7: MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges
MicroNet Prevents Distal Embolization and Other © Vascular Disease Challenges Inspire + Proprietary technology + Ultrathin PET* mesh provides meaningful clinical benefit versus conventional devices + Provides revascularization benefit + MicroNet acts as “safety net’ by offering greater vessel area c
Slide 8: Large Addressable Market
Large Addressable Market Embolic Prevention Products Market Opportunity inspireMD MGuard™* re) PVGuard™ * MGuard isa bare metal stent scafoks $1.7B $500M $675M $1.7B v v (FDA IDE drat protocal synopsis) 2017E Planned Submission 2018E Planned Submission Coronary AMI & SVG Carotid Neurovascular Periph
Slide 9: Positive CGuard Data
Positive CGuard Data inspirelMD Clinical trials support peri- and post-procedural safety and efficacy + CARENET: 30-patient safety and efficacy clinical trial’ * Independent investigator-initiated clinical study: 30 patients with internal carotid artery stenosis? + PARADIGM-101: 101-patient trial ev
Slide 10: CGuard Data Presentation at TCT 2016
CGuard Data Presentation at TCT 2016 inspireMD 12-month follow up data of PARADIGM-101 Study of CGuard EPS + No device-related adverse events at 12 months + Vessel narrowing was reduced from 83+9% to only 6.745% (p<0.001) by independent core lab analysis + Peri-procedural death/major stroke/myocardi
Slide 11: Broad EU Commercialization Support from a Growing Neurovascular Leader
Broad EU Commercialization Support from a go NS. Growing Neurovascular Leader Inspir ‘eMD Penumbra 9 + Strategic distribution agreement with Penumbra * 18 European markets with opportunity to expand * Comprehensive neurovascular product portfolio + CGuard is a synergistic product offering * Growing
Slide 12: Expanding Pipeline Opportunities with MicroNet
Expanding Pipeline Opportunities with MicroNet inspireMD Commercial + CE Mark Cleared + 12-month MASTER |, II MGuard™ Corona 7: EPS ss Commercial + CE Mark Cleared Exploring Market RGuard™ CGuard™ CARENET Trial Opportunity Renal* Carotid PARADIGM all-comer trials Wissgott 2016 data EPS FDA IDE draft
Slide 13: Flow Diversion for Neurovascular Aneurysms
Flow Diversion for Neurovascular Aneurysms inspireMD Objective + Seal the aneurysm and prevent rupture Current device therapies * Coils to pack the aneurysm ¢ Flow diverters * Highly flexible, dense metal “tube” + Placed in main artery to seal off aneurysm and cause aneurysm thrombosis + Precise del
Slide 14: Innovation Enables Growth in the Neurovascular Market
Innovation Enables Growth in the Neurovascular ~~ “e Market InspireMD Flow Diversion for Unruptured Brain Aneurysms Next Generation Technology * Aneurysm Therapy (all types): $550M* + Flow diverters are estimated to be 25% of the aneurysm market + Neurovascular products: estimated 15% CAGR from 2010
Slide 15: InspireMD Flow Diverter Advantage
InspireMD Flow Diverter Advantage inspireMD + Low profile, flexible, open cell scaffold = Easy to deliver + Low metal ratio = Potential for reduced anti-thrombosis medication + Re-accessible through MicroNet = Allows for further treatment, if needed which is impossible with current flow diverters *
Slide 16: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD * Proprietary platform technology supported by a robust intellectual property portfolio. * Continue to strengthen and broaden patent protection globally. + Progress over the last year imparts important rights on existing products and technologies and will en
Slide 17: Upcoming Anticipated Milestones
Upcoming Anticipated Milestones inspireMD 2016 2017 2018 2018E NGuard Flow development Gua cour Diverter: 2017 towards CE Mark PVGuard CE submission Mark Planned Submission approval received: Q4 launch in CGuard: 2017 US. IDE CGuard . approval and CGuard faunch in India: approval and H2 2017 ch H1 2
Slide 18: Leadership
aN Leadership inspirelMD Significant track records of success President and CEO cBostone (Pfizer) in Fi cco Delcatho. ® anciodsnamics BELERT = é- Vice Chaiman Byer GF _ meters ge’ Director Boston. ore LUTONIX Director | = Fidelity Director OneartFlow Cordis. patie Director ,} fe Rees re et aA 18
Slide 19: Financial Snapshot
Financial Snapshot inspireMD NYSE MKT: NSPR, NSPR.WS Average Volume (3 Months): 358 K Shares Outstanding (9/30/16): 14M Shares Outstanding Including Future Pref. 36M Stock Conv. (9/30/16): Market Capitalization (10/14/16): $2.7M Total Cash: $10.5 M as of 9/30/2016 US Headquarters: Boston, MA Interna
Slide 20: Investment Highlights
Investment Highlights inspireMD + Revenue growth driven by broader EU and Latin American launch of CGuard + Strategic distribution partnership with Penumbra (NYSE: PEN) + Strong, and growing, direct sales teams across key countries + Multiple and consistent clinical trial results using CGuard in a b
Slide 21: inspireMD
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com